Bristol-Myers Squibb (BMS) is reported to have reached a deal to license its AIDS drug Reyataz to two generic drug manufacturers in the developing world free of charge, one of the first such agreements involving a second-line AIDS treatment.Under the deal to be announced today, BMS will grant a royalty-free license to South Africa’s Aspen PharmaCare Holdings and India’s Emcure Pharmaceuticals to make and sell atazanavir, the molecule Reyataz is based on, in sub-Saharan Africa, The Wall Street Journal reported.Reyataz is a relatively new AIDS drug considered especially effective when used in a “cocktail” combination with Abbott Laboratories’ Norvir. BMS received US marketing approval for Reyataz in 2003. The drug’s patent runs out in 2017.
BMS reaches free licensing deal for Reyataz in developing world
Bristol-Myers Squibb (BMS) is reported to have reached a deal to license its AIDS drug Reyataz to two generic drug manufacturers in the developing world free of charge, one of the first such agreements involving a second-line AIDS treatment.